Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 701–800 of 1,003
Lapses at the New England Journal of Medicine
Smith, R. W. (2006) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.99.8.380 · Cited by 49
Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies
Zaman, F. Y., Orchard, S. G., Haydon, A. M., & Zalcberg, J. R. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01882-8 · Cited by 48
“Rofecoxib in chemoprevention of colorectal adenomas, and in adjuvant CRC treatment trials was also associated with an increased risk of cardiovascular events [51, 52].”
BackgroundDoes the varied use of NSAIDs explain the differences in the risk of myocardial infarction?
van Staa, T. P., Rietbrock, S., Setakis, E., & Leufkens, H. G. M. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01991.x · Cited by 50
Sakamoto, C., & Soen, S. (2010) · Digestion · doi:10.1159/000318746 · Cited by 48
A Day in the Life of Oscar the Cat
Dosa, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078108 · Cited by 53
Impediments to Clinical Research in the United States
Kramer, J. M., Smith, P. B., & Califf, R. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.341 · Cited by 46
Krijthe, B. P., Heeringa, J., Hofman, A., Franco, O. H., & Stricker, B. H. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004059 · Cited by 45
Kaur, J. P., Bhardwaj, A., Huang, Z., & Knaus, E. E. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.01.130 · Cited by 47
Inappropriate prescribing in geriatric patients
Barry, P. J., Gallagher, P., & Ryan, C. A. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0008-3 · Cited by 61
Biava, M., Porretta, G. C., Poce, G., Battilocchio, C., Alfonso, S., Rovini, M., Valenti, S., Giorgi, G., Calderone, V., Martelli, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200715n · Cited by 47
Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs
Bolten, W. W. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.036269 · Cited by 47
Ding, C., Cicuttini, F., & Jones, G. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.022 · Cited by 46
The Role of Traditional Cardiovascular Risk Factors Among Patients with Rheumatoid Arthritis
Brady, S. R. E., de Courten, B. V., Reid, C. M., Cicuttini, F., de Courten, M., & Liew, D. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080404 · Cited by 53
Celecoxib and Heterotopic Bone Formation After Total Hip Arthroplasty
Lavernia, C. J., Contreras, J. S., Villa, J. M., & Rossi, M. D. (2013) · The Journal of Arthroplasty · doi:10.1016/j.arth.2013.06.039 · Cited by 46
“On the other hand, COX-2 inhibitors have been related with increased cardiovascular risk [17–19].”
BackgroundCorral, R. S., Iñiguez, M. A., Duque, J., López‐Pérez, R., & Fresno, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209856 · Cited by 46
“Nevertheless, Cox-2specific inhibitors may significantly increase cardiovascular risk (Bresalier et al., 2005) and some clinical trials indicate that the Cox-2 inhibitor Rofecoxib has little effect on proliferation or apoptosis of colorectal cancer liver metastases (Fenwick et al.”
BackgroundUse of nonsteroidal anti-inflammatory drugs in the older adult
Fowler, T., Durham, C. O., Planton, J., & Edlund, B. J. (2014) · Journal of the American Association of Nurse Practitioners · doi:10.1002/2327-6924.12139 · Cited by 51
“Two highly selective COX-2 inhibitors, rofecoxib and valdecoxib, were removed from the U.S. market because of numerous side effects, including the significant increase in cardiovascular risk (Bresalier et al., 2005; Nussmeier et al., 2005).”
BackgroundAn evidence‐based update of the use of analgesics in dentistry
Ong, C. K. S., & Seymour, R. A. (2008) · Periodontology 2000 · doi:10.1111/j.1600-0757.2008.00225.x · Cited by 46
Practice Advisory on the Appropriate Use of NSAIDs in Primary Care
Ho, K., Cardosa, M. S., Chaiamnuay, S., Hidayat, R., Hồ, H. Q. T., Kamil, O., Mokhtar, S. A., Nakata, K., Navarra, S., Nguyen, V. H., et al. (2020) · Journal of Pain Research · doi:10.2147/jpr.s247781 · Cited by 55
Curtis, S., Bockow, B. I., Fisher, C., Olaleye, J., Compton, A., Ko, A. T., & Reicin, A. S. (2005) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-6-58 · Cited by 46
“However, results from longer-term, placebo-controlled trials with rofeocoxib and celecoxib suggest that use of COX-2 selective inhibitors are associated with an increased incidence of adverse CV events compared to placeb [12,13].”
Misra, R., Sharma, B., Gupta, R., Pandya, S., Agarwal, S., Agarwal, P., Grover, S., Sarma, P., & Wangjam, K. (2008) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60373-1 · Cited by 48
Pathi, S. S., Li, X., & Safe, S. H. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22010 · Cited by 46
Dassesse, T., de Leval, X., de Leval, L., Pirotte, B., Castronovo, V., & Waltregny, D. (2006) · European Urology · doi:10.1016/j.eururo.2006.01.036 · Cited by 47
Schmidt, M., Lamberts, M., Olsen, A. S., Fosbøl, E. L., Niessner, A., Tamargo, J. L., Rosano, G. M. C., Agewall, S., Kaski, J. C., Kjeldsen, K. P., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv054 · Cited by 49
Understanding the NSAID related risk of vascular events
Vonkeman, H. E., Brouwers, J. R. B. J., & van de Laar, M. A. F. J. (2006) · BMJ · doi:10.1136/bmj.332.7546.895 · Cited by 51
Obeid, S., Libby, P., Husni, M. E., Wang, Q., Wisniewski, L. M., Davey, D. A., Wolski, K. E., Xia, F., Bao, W., Walker, C., et al. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac015 · Cited by 49
Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis
Chang, J. H., Vacher, J., Yao, B., Fan, X., Zhang, B., Harris, R. C., & Zhang, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5589 · Cited by 225
“There is a clear molecular link between COX-2 and COX-2-derived PGE2 and CRC progression [1, 2].”
BackgroundInfluentialXie, W., Xiao, S., Huang, Y., Sun, X., & Zhang, Z. (2019) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x19895492 · Cited by 46
Do proton‐pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?
Rahme, E., Barkun, A. N., Toubouti, Y. M., Scalera, A., Rochon, S., & LeLorier, J. (2007) · Arthritis Care & Research · doi:10.1002/art.22764 · Cited by 46
End-of-Life Care for the Hospitalized Patient
Pantilat, S. Z., & Isaac, M. (2008) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.11.001 · Cited by 48
The Cardiovascular Pharmacology of COX-2 Inhibition
Fries, S., & Großer, T. (2005) · Hematology · doi:10.1182/asheducation-2005.1.445 · Cited by 45
Bottone, F. G., Moon, Y., Alston‐Mills, B., & Eling, T. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089607 · Cited by 45
“…of tumorigenicity, but the global pattern of genes altered after exposure to these compounds needs to be considered particularly in light of recent concerns that the use of selective Cox inhibitors in humans over long periods may result in dangerous cardiovascular events (Bresalier et al., 2005).”
BackgroundCOX‐2 has a Critical Role During Incorporation of Structural Bone Allografts
O’Keefe, R. J., Tiyapatanaputi, P., Xie, C. L., LI, T. F., CLARK, C., Zuscik, M. J., Chen, D., Drissi, H., Schwarz, E. M., & Zhang, X. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.012 · Cited by 45
Francis, S. O., Mahlberg, M. J., Johnson, K. R., Ming, M. E., & Dellavalle, R. P. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.014 · Cited by 51
Velentgas, P., West, W., Cannuscio, C. C., Watson, D. J., & Walker, A. M. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1192 · Cited by 45
“Merck’s withdrawal of rofecoxib from the market in September 2004 was based on results of the APPROVe adenomatous polyp prevention trial, which showed an increased risk of thrombotic cardiovascular events for patients taking 25 mg rofecoxib compared with placebo that became evident after 18 months of treatment.(1) Rat…”
MethodCardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications
Bello, A. E., & Holt, R. J. (2014) · Drug Safety · doi:10.1007/s40264-014-0207-2 · Cited by 50
“market in 2004 after the results of a placebo-controlled trial found almost a doubling of serious CV events [10] and that the risk was elevated up to a year after stopping the drug [11].”
ResultCapone, M. L., Tacconelli, S., Rodríguez, L. G., & Patrignani, P. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70310-8 · Cited by 44
“and valdecoxib [4, 24, 25, 35].”
Developing drug prototypes: pharmacology replaces safety and tolerability?
Cohen, A. F. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3227 · Cited by 46
Distinct Role of Kruppel-like Factor 11 in the Regulation of Prostaglandin E2 Biosynthesis
Buttar, N. S., DeMars, C. J., Lomberk, G. A., Ilyas, S. I., Bonilla‐Velez, J., Achra, S., Rashtak, S., Wang, K. K., Fernández-Zapico, M. E., & Urrutia, R. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.077065 · Cited by 44
“[12-15] However, in recent investigations, it has been recognized that long-term COX-2 inhibition is not safe due to increased cardiac and cerebrovascular side effects.[16-18] The explanation for such complications in the setting of COX-2 inhibition is an ongoing production of arachidonic acid by phospholipase A2.”
BackgroundBraun, F., Al‐Yacoub, N., Plötz, M., Möbs, M., Sterry, W., & Eberle, J. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.316 · Cited by 44
“the selective COX-2 inhibitors, and valdecoxib and rofecoxib had to be recalled from the market (Bresalier et al., 2005; Nussmeier et al., 2005).”
BackgroundZatelli, M. C., Luchin, A., Tagliati, F., Leoni, S., Piccin, D., Bondanelli, M., Rossi, R., & Uberti, E. C. D. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0114 · Cited by 47
“These encouraging results should, however, undergo strict clinical verification, given the relevant cardiovascular and thrombo-embolic toxicity correlated to the prolonged use of COX-2 inhibitors (Bresalier et al. 2005, Nussmeier et al. 2005, Solomon et al. 2005).”
Patrono, C., & Baigent, C. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.696 · Cited by 44
“The Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial was designed to evaluate the hypothesis that 3 years of treatment with rofecoxib (25 mg daily) would reduce the risk of recurrent adenomatous polyps among patients with a history of colorectal adenomas.(25) In APPROVe, a total of 46 patients in the rofecoxib gr…”
BackgroundInfluentialAGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review
Liang, P. S., Shaukat, A., & Crockett, S. D. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.014 · Cited by 48
Essential Polyunsaturated Fatty Acids, Inflammation, Atherosclerosis and Cardiovascular Diseases
de Lorgeril, M. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_13 · Cited by 45
The role of the cylooxygenase pathway in nociception and pain
Bingham, S., Beswick, P., Blum, D., Gray, N. M., & Chessell, I. P. (2006) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2006.09.001 · Cited by 51
Koo, B., Kim, Y., Park, K. W., Yang, H., Kwon, D., Chung, J.-W., Hahn, J., Lee, H., Park, J., Kang, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61295-1 · Cited by 44
Aoki, T., Yamaguchi, H., Naito, H., Shiiki, K., Izawa, K., Ota, Y., Sakamoto, H., & Kaneko, A. (2006) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2006.01.026 · Cited by 46
Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine
Praticò, D., & Dogné, J.-M. (2005) · Circulation · doi:10.1161/circulationaha.104.524231 · Cited by 50
Do Non-steroidal Anti-inflammatory Drugs Cause Exacerbations of Inflammatory Bowel Disease?
Feagins, L. A., & Cryer, B. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1042-7 · Cited by 44
“Unfortunately, these drugs are not entirely devoid of GI toxicity, and enthusiasm for their use has been dampened substantially by the realization that the COX-2selective NSAIDs are associated with cardiovascular risks [4, 5].”
BackgroundOsteoarthritic pain: a review of current, theoretical and emerging therapeutics
Read, S., & Dray, A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.5.619 · Cited by 46
“Studies comparing COX-2 inhibitors with placebo and observational studies/meta-analyses comparing COX-2 inhibitors with non-selective NSAIDs are cited as evidence of a differentiated cardiovascular risk [7-12] .”
ResultImpact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans
Lee, T. A., Bartle, B., & Weiss, K. B. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.003 · Cited by 47
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
Harris, R., Beebe, & Alshafie (2012) · Journal of Experimental Pharmacology · doi:10.2147/jep.s23826 · Cited by 43
Clinical pharmacology of celecoxib, a COX-2 selective inhibitor
Antoniou, K., Malamas, M., & Drosos, A. A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1719 · Cited by 46
“Based on the already mentioned anti-tumour activity of COX-2 inhibitors, trials were commenced with celecoxib (the APC [adenoma prevention with celecoxib] trial) and rofecoxib (the APPROVE [adenomatous polyp prevention on Vioxx] trial), which were prematurely stopped due to a significant excess of adverse CV effects i…”
MethodColorectal Cancer Chemoprevention: Is This the Future of Colorectal Cancer Prevention?
Manzano, A., & Pérez‐Segura, P. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/327341 · Cited by 43
“The complete analysis of the cardiotoxicity and cardiovascular event incidence of these trials has been published in several articles (Table 2) [24, 25].”
BackgroundLipoxygenase and Cyclooxygenase Pathways and Colorectal Cancer Prevention
Rao, C. V., Janakiram, N. B., & Mohammed, A. (2012) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0146-1 · Cited by 47
“Clinical trials with celecoxib and rofecoxib have shown that these agents provide significant chemopreventive efficacy against sporadic polyp development; however, the requirement of high doses and the increased occurrence of cardiovascular events have been deterrents for widespread clinical application [26–28].”
BackgroundGreenhough, A., Wallam, C. A., Hicks, D. J., Moorghen, M., Williams, A. C., & Paraskeva, C. (2010) · Oncogene · doi:10.1038/onc.2010.94 · Cited by 49
“Recent clinical trials have brought to light the increased risk of adverse cardiovascular events associated with the use of highly selective COX-2 inhibitors for long-term colorectal cancer prevention (Bresalier et al., 2005).”
Kaye, A. D., Cornett, E. M., Helander, E. M., Menard, B. L., Hsu, E. S., Hart, B. M., & Brunk, A. J. (2017) · Anesthesiology Clinics · doi:10.1016/j.anclin.2017.01.006 · Cited by 43
“The APPROVe Trial showed that rofecoxib used with hopes of preventing recurrence of adenomatous polyps in patients with a history of colorectal cancer was associated with higher risk of thrombotic cardiovascular events.(14) Another large study evaluated parecoxib after cardiac surgery, and revealed that it too was ass…”
MethodDebucquoy, A., Roels, S., Goethals, L., Libbrecht, L. J., Cutsem, E. V., Geboes, K., PENNINCKX, F. M., D’Hoore, A., McBride, W. H., & Haustermans, K. M. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.08.006 · Cited by 46
“Selective COX-2 inhibitors have been associated with an increased risk of cardiovascular events when used to prevent colon cancer in comparison with placebo [40–42].”
BackgroundNathan, D. M. (2007) · Diabetes Care · doi:10.2337/dc06-2600 · Cited by 51
de Carvalho, P. S., Maróstica, M., Gambero, A., & Pedrazzoli, J. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.034 · Cited by 43
Chan, P.-S., Caron, J. P., & Orth, M. (2007) · American Journal of Veterinary Research · doi:10.2460/ajvr.68.7.709 · Cited by 49
COX-2 expression in chondrosarcoma: A role for celecoxib treatment?
Schrage, Y. M., Machado, I., Meijer, D., Bruijn, I. H. B., van den Akker, B. E., Taminiau, A. H. M., Kalinski, T., Llombart‐Bosch, A., & Bovée, J. V. M. G. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.002 · Cited by 43
“Celecoxib trialswere discontinuedearlier(25) androfecoxibwaswithdrawn by theFDA.(26) However, children and adolescents are at low risk of cardiovascular disease, which renders the use of celecoxib relatively safe.”
BackgroundSpeed, Safety, and Industry Funding — From PDUFA I to PDUFA VI
Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmhle1710706 · Cited by 47
Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs
Anwar, A., Anwar, I. J., & Delafontaine, P. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.03.006 · Cited by 47
Kristensen, L. E., Jakobsen, A. K., Askling, J., Nilsson, F., & Jacobsson, L. (2015) · Arthritis Care & Research · doi:10.1002/acr.22555 · Cited by 42
“This is in contrast to what has been reported from RCTs and meta-analyses and is likely due to a conscious clinical choice by the treating physicians (9,11,26).”
BackgroundResultCoxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials
Rodríguez, L. A. G., Soriano, L. C., Tacconelli, S., & Patrignani, P. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-30331-9_4 · Cited by 46
Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model
Ahmad, S., Panda, B. P., Kohli, K., Fahim, M., & Dubey, K. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1299768 · Cited by 42
Regulation of inflammation in cancer by dietary eicosanoids
Yang, H., Rothenberger, E., Zhao, T., Fan, W., Kelly, A. G., Attaya, A., Fan, D., Panigrahy, D., & Deng, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108455 · Cited by 43
Balmaceda, C. M. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-27 · Cited by 50
“Because COX-2 has substantial expression in cardiovascular and renal tissue, concerns have been raised regarding potential adverse cardiovascular and renal effects associated with the use of these agents [21-24].”
BackgroundKrueger, K., Lino, L., Dore, R. K., Radominski, S., Zhang, Y., Kaur, A., Simpson, R., & Curtis, S. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.082388 · Cited by 42
Tumor Promotion as a Target of Cancer Prevention
Marks, F., Fürstenberger, G., & Müller‐Decker, K. (2007) · Springer eBooks · doi:10.1007/978-3-540-37696-5_3 · Cited by 42
Coxibs, non‐steroidal anti‐inflammatory drugs and cardiovascular risk
Hermann, M., & Ruschitzka, F. T. (2006) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2006.01056.x · Cited by 49
Hur, C., Chan, A. T., Tramontano, A. C., & Gazelle, G. S. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g493 · Cited by 45
Platelets, Cyclooxygenases, and Colon Cancer
Guillem‐Llobat, P., Dovizio, M., Alberti, S., Bruno, A., & Patrignani, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.04.008 · Cited by 44
Raghavendra, N. M., Jyothsna, A., Alapati, V. R., & Subrahmanyam, C. V. S. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.062 · Cited by 41
Clinical trials in stem cell transplantation: guidelines for scientific and ethical review
Lo, B., Kriegstein, A. R., & Grady, D. G. (2008) · Clinical Trials · doi:10.1177/1740774508096705 · Cited by 41
“In recent clinical trials, the drug torcetrapib increased mortality [22], rofecoxib increased the risk of heart attacks [23,24], and superagonistic monoclonal anti-CD4 antibodies caused cytokine storm and circulatory collapse [8,9], despite encouraging preclinical results.”
BackgroundGiordano, N. G., Fioravanti, A., Papakostas, P., Montella, A., Giorgi, G., & Nuti, R. (2009) · Current Therapeutic Research · doi:10.1016/j.curtheres.2009.05.004 · Cited by 41
The Future of Clinical Trials in Cardiovascular Medicine
Solomon, S. D., & Pfeffer, M. A. (2016) · Circulation · doi:10.1161/circulationaha.115.020723 · Cited by 44
Bouck, Z., Mecredy, G. C., Ivers, N. M., Barua, M., Martin, D., Austin, P. C., Tepper, J. D., & Bhatia, R. S. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.4273 · Cited by 41
Composite Endpoints for Clinical Trials: Current Perspectives
Kleist, P. (2007) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200721030-00001 · Cited by 45
Somatostatin inhibits colon cancer cell growth through cyclooxygenase‐2 downregulation
Colucci, R., Blandizzi, C., Ghisu, N., Florio, T., & Tacca, M. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.268 · Cited by 41
“However, owing to serious concerns on safety of COX-2 inhibitors, the long-term use of these drugs in cancer patients is presently questioned (Bresalier et al., 2005), and therefore it appears of interest to identify alternative strategies to downregulate COX-2 expression/ function at the level of…”
BackgroundReiff, A. O., Lovell, D. J., van Adelsberg, J., Kiss, M. H. B., Goodman, S. I., Zavaler, M. F., Chen, P.-Y., Bolognese, J. A., Cavanaugh, P. F., Reicin, A. S., et al. (2006) · PubMed · Cited by 41
Self-citationPrevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 54
“However, the treatments in this trial were stopped prematurely owing to safety concerns about cardiovascular risks of selective COX-2 inhibitors, noted in other trials (Bresalier et al., 2005; Solomon et al., 2005).”
ResultKim, N., Kim, C. H., Ahn, D., Lee, K. S., Cho, S., Park, J. H., Lee, M. K., Kim, J. S., Jung, H. C., & Song, I. S. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05599.x · Cited by 41
Ilowite, N. T., & Laxer, R. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6581-4.10006-8 · Cited by 42
Chan, E. S. L., Zhang, H., Fernandez, P., Edelman, S. D., Pillinger, M. H., Ragolia, L., Palaia, T. A., Carsons, S. E., & Reiss, A. B. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2109 · Cited by 42
“11) [4].”
Ahmad, A. S., Ahmad, M., Maruyama, T., Narumiya, S., & Doré, S. (2010) · AGE · doi:10.1007/s11357-010-9135-y · Cited by 44
“Unfortunately, clinical trials associate COX-2 inhibitors with enhanced risk of cardiovascular complications (Bresalier et al. 2005; Graham et al. 2005).”
BackgroundDrug Insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now?
Spektor, G., & Fuster, V. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0214 · Cited by 44
Treatment of ankylosing spondylitis
Sarı, İ., Öztürk, M. A., & Akkoç, N. (2015) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1401-79 · Cited by 40
Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal
Davies, N. M., Reynolds, J. K., Undeberg, M. R., Gates, B. J., Ohgami, Y., & Vega‐Villa, K. R. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.11.1643 · Cited by 45
COX-2 Inhibitors for the Prevention of Heterotopic Ossification After THA
Vasileiadis, G. I., Sioutis, I. C., Mavrogenis, A. F., Vlasis, K. G., Babis, G. C., & Papagelopoulos, P. J. (2011) · Orthopedics · doi:10.3928/01477447-20110427-23 · Cited by 40
Fan, J., Li, R., Wang, H., He, X. J., Nguyen, T. P., Letteri, R. A., Zou, J., & Wooley, K. L. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00931c · Cited by 40
The Anti-Cancer Effect of COX-2 Inhibitors on Gastric Cancer Cells
Cho, S., Kim, N., Kim, J. S., Jung, H. C., & Song, I. S. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9787-3 · Cited by 40
“Rofecoxib (Vioxx) was withdrawn from market in 2004 after interim analysis of APPROVe (Adenomatous Polyps Prevention on VIOXX) trial [36].”
Yanaoka, K., Oka, M., Yoshimura, N., Deguchi, H., Mukoubayashi, C., Enomoto, S., Maekita, T., Inoue, I., Ueda, K., Utsunomiya, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24862 · Cited by 40
Daniels, S., Robbins, J. L., West, C. R., & Nemeth, M. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.06.003 · Cited by 45
Cardiovascular risk, hypertension, and NSAIDs
White, W. B. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0020-3 · Cited by 40
Ungprasert, P., Matteson, E. L., & Thongprayoon, C. (2015) · Stroke · doi:10.1161/strokeaha.115.011678 · Cited by 46
Moneer, A. A., Mohammed, K. O., & El‐Nassan, H. B. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12712 · Cited by 46
“(Kenilworth, NJ, USA) due to its adverse cardiovascular side-effects (21).”
BackgroundEvolution of Topical NSAIDs in the Guidelines for Treatment of Osteoarthritis in Elderly Patients
Arnstein, P. M. (2012) · Drugs & Aging · doi:10.2165/11631550-000000000-00000 · Cited by 43
Treat to target in axial spondyloarthritis: From its concept to its implementation
Dougados, M. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102398 · Cited by 39
Yang, H., Cheng, H., Sheu, B., HUNG, K. ‐., Liou, M.-Y., & Wu, J.-J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03224.x · Cited by 39
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.